Plecanatide: Completed Phase IIb enrollment

Synergy completed enrollment of about 350 patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating 0.3, 1, 3 and 9 mg oral plecanatide once daily for 12 weeks. ...